Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
BTK inhibitor
Zanubrutinib
Brukinsa · Zanu
A highly selective BTK inhibitor with the lowest cardiovascular signal of the class; tumor lysis is its main renal concern.
MildBTK inhibitor (2nd generation) · approved 2019
CLL/SLLMantle-cell lymphomaMarginal-zone lymphomaWaldenström macroglobulinemiaFollicular lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is not a prominent signal. Cardiovascular toxicity (atrial fibrillation, hypertension) is lower than ibrutinib in pooled and head-to-head (ASPEN, ALPINE) analyses. Tumor lysis can occur with rapid cytoreduction of bulky CLL/lymphoma; renal events are case-level and not well quantified.
Source: Moslehi et al., Blood Adv 2024 (pooled CV analysis)
Mechanism of kidney injury
High BTK selectivity limits the off-target endothelial/kinase effects that drive ibrutinib's hypertension, so atrial fibrillation and hypertension rates are the lowest in the class. AKI is predominantly hemodynamic or due to tumor lysis (hyperuricemia/hyperphosphatemia with intratubular crystal/urate injury) when high-burden disease responds.
Clinical presentation
Usually stable renal function; tumor-lysis labs (hyperkalemia, hyperphosphatemia, hyperuricemia, rising creatinine) in high-risk disease. Lower hypertension/atrial fibrillation than ibrutinib.
Onset
Tumor lysis early (first cycle); otherwise renal function typically stable.
Reversibility
Variable
Anticancer mechanism
Next-generation, highly selective covalent BTK inhibitor designed for complete and sustained BTK occupancy with minimal off-target kinase activity, used in CLL/SLL, mantle-cell lymphoma, marginal-zone lymphoma, Waldenström macroglobulinemia and follicular lymphoma.
Management
Manage tumor lysis with hydration and rasburicase/allopurinol and electrolyte correction; supportive care. Dose-modify (from 160 mg twice daily or 320 mg once daily) for severe toxicity.
Risk factors
- High tumor burden / bulky disease
- Volume depletion
- Pre-existing CKD
Prevention
- TLS risk stratification with hydration and urate-lowering therapy
- Monitor renal function and electrolytes during early response
- Blood-pressure monitoring (lower but non-zero risk)
Note · Renal toxicity is largely a tumor-lysis phenomenon rather than a direct drug effect; zanubrutinib has the most favorable cardiovascular tolerability of the BTK-inhibitor class.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-to-moderate renal impairment; in severe renal impairment and on dialysis, exposure changes are modest and no dose adjustment is generally required, though data are limited. Hepatic impairment, not renal, drives reduction; minimal renal excretion of unchanged drug.
Dialyzability & ESKD dosing
Not meaningfully dialyzable — highly protein-bound, hepatically (CYP3A) cleared small molecule. No supplemental post-HD dose needed.
Differential diagnosis
Distinguish tumor-lysis AKI (urate/phosphate profile, early) from prerenal azotemia and CLL-intrinsic kidney disease. Because cardiovascular and hypertensive effects are lowest in the class, a marked BP rise should prompt a search for other causes.
Monitoring
- Tumor-lysis labs during early cytoreduction of bulky disease
- Serum creatinine and electrolytes
- Blood pressure and rhythm assessment periodically (lowest CV risk of class but still monitored)
Key trials & series
- Moslehi et al., Blood Adv 2024 — pooled CV analysis (10 studies; ASPEN and ALPINE head-to-head) showing lower atrial fibrillation/hypertension vs ibrutinib
Clinical pearls
- Zanubrutinib has the lowest atrial-fibrillation and hypertension rates among BTK inhibitors — the renal story is mostly tumor lysis.
- Anticipate and prophylax against TLS when debulking high-burden CLL/lymphoma.
- Even on dialysis, exposure changes are modest and generally do not require dose adjustment, though data remain limited.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of btk inhibitors.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- Atrial fibrillation, ventricular arrhythmia
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Bleeding, hypertension
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkCardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.Moslehi JJ et al. · Blood Adv 2024 · PMID 38502198Pooled analysis (10 studies; ASPEN/ALPINE) showing lower atrial fibrillation and hypertension than ibrutinib.PMIDRenal involvement in chronic lymphocytic leukemia.Wanchoo R et al. · Clin Kidney J 2018 · PMID 30288263Onconephrology review of CLL kidney disease and tumor lysis with novel agents.PMIDHypertension and incident cardiovascular events after next-generation BTKi therapy initiation.Chen ST et al. · J Hematol Oncol 2022 · PMID 35836241BTKi hypertension as a class effect; context for zanubrutinib's lower cardiovascular signal.PMIDAcute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.Kala J et al. · Kidney360 2024 · PMID 39186376Onconephrology review covering BTK-inhibitor renal effects.PMIDHypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.van Dorst DCH et al. · Circ Res 2021 · PMID 33793337Review of BTK-inhibitor–associated hypertension mechanisms (class context).PMIDOnconephrology: Update in Anticancer Drug-Related Nephrotoxicity.García-Carro C et al. · Nephron 2022 · PMID 35717937Onconephrology review situating BTK-inhibitor renal effects among targeted agents.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494Tumor lysis syndrome pathophysiology and AKI management (the principal zanubrutinib renal risk).
Related agents
Other agents sharing the same signature kidney injury.